COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hyperbaric Oxygen for Traumatic and Non-traumatic Brain Injury (HYBOBI2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01986205
Recruitment Status : Recruiting
First Posted : November 18, 2013
Last Update Posted : March 10, 2020
Information provided by (Responsible Party):
Lindell Weaver, Intermountain Health Care, Inc.

Brief Summary:

The purpose of this study is to examine whether 40 hyperbaric oxygen sessions has effect on long-term symptoms after brain injury. This study will enroll 90 individuals with persistent problems 6 months to 10 years after a brain injury. These individuals will be randomized to receive either oxygen or air in a pressurized hyperbaric chamber. Participants will receive 40 daily hyperbaric chamber sessions.

Participants will have a series of tests and questionnaires before they begin their chamber sessions, after they complete 40 sessions, and 6 months after they joined the study. These tests include computer-based and pencil-and-paper questionnaires and thinking tests, brain imaging, a neurological examination, and an eye exam. Participants will also be asked to provide blood for future research.

After the 6-month tests are complete, all participants will receive 40 hyperbaric oxygen sessions, then undergo the same tests at 9 months and 12 months.

Condition or disease Intervention/treatment Phase
Brain Injury, Chronic Combination Product: Hyperbaric Oxygen Combination Product: Minimal pressure air Phase 2

Detailed Description:

This is a single center, randomized, double-blind study with a subsequent open-label intervention period to explore whether a course of hyperbaric oxygen can ameliorate persistent symptoms after brain injury. In this study, adult men and women with persistent symptoms 6 months to 10 years after injury will be randomized to receive 40 hyperbaric oxygen sessions (100% oxygen at 1.5 atmospheres absolute, 60 minutes door-to-door) or sham chamber sessions (room air chamber excursion at near-ambient pressure, 60 minutes door-to-door). Chamber sessions will be provided Monday through Friday, excluding holidays, and participants will have up to 12 weeks to complete their 40 sessions.

Participants will be evaluated before the chamber sessions, at 13 weeks, and at 6 months. Assessments include self-administered questionnaires, neuropsychological function, a brief neurological examination, electroencephalography, visual function tests, and a neuro-optometry evaluation. These outcome tools will measure symptoms and deficit at the time of enrollment and subsequent evaluations, and provide insight into whether hyperbaric oxygen can play a role in recovery from brain injury.

Once the participants have completed their 6 month evaluations, they will enter an open intervention group, receiving 40 hyperbaric sessions at 1.5 atmospheres absolute for 60 minutes. Participants will have up to 12 weeks to complete these sessions. Participants will be evaluated after the second set of chamber sessions (at 9 months and again at 12 months). Individuals will then be assessed annually until study closure (12-month follow-up of the last enrolled participant).

Participants will be asked to provide blood for long-term storage of serum, plasma, and DNA for future investigations, including apolipoprotein E genotype.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind Randomized Trial of Hyperbaric Oxygen Versus Sham for Persistent Symptoms After Brain Injury
Actual Study Start Date : September 6, 2017
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Arm Intervention/treatment
Experimental: Hyperbaric Oxygen
100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
Combination Product: Hyperbaric Oxygen
Hyperbaric oxygen (USP oxygen >99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
Other Names:
  • HBO2
  • HBOT
  • HBO
  • Hyperbaric oxygen therapy

Placebo Comparator: Minimal pressure air
Regular air at minimal pressurization for 60 minutes, 40 sessions
Combination Product: Minimal pressure air
Room air delivered in a hyperbaric chamber with minimal pressurization.
Other Name: Room air

Primary Outcome Measures :
  1. Neurobehavioral Symptom Inventory [ Time Frame: 13 weeks ]
    Participant-reported symptom rating of post-concussive symptoms

Secondary Outcome Measures :
  1. Neurobehavioral Symptom Inventory [ Time Frame: 6 months ]
    Participant-reported symptom rating of post-concussive symptoms

  2. Incidence of myopia [ Time Frame: 13 weeks ]
    Myopic visual changes after chamber sessions

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults, age 18-70 years, both men and women
  • Able to speak and read English as primary language
  • Able and willing to provide written informed consent for study participation.
  • Able and willing to complete outcome assessments and provide blood and urine samples as required by the study protocol.
  • Able to tolerate the chamber environment and hood placement and to equalize middle ear pressure.
  • Past history of at least one brain injury with persistent symptoms that meets all of the following criteria:

    • Brain injury of non-stroke etiology that occurred at least 6 months but no more than 10 years prior to enrollment.
    • At least 3 of the following persistent symptoms from the injury: headaches, dizziness or balance problems, blurred vision, tiredness/fatigue or sleep problems, seizures, remembering things or solving problems, managing stress or emotional upsets, controlling temper/irritability, depression, anxiety, post-traumatic stress, or ringing in the ears.
  • Normal thyroid stimulating hormone and hematocrit value greater than 35% within the previous 6 months.

Exclusion Criteria:

  • Contraindications to hyperbaric oxygen

    • Insulin-dependent diabetes mellitus, or diabetes mellitus that is not reasonably controlled.
    • Uncontrolled seizure disorder (participants must be on therapy and seizure-free for at least 6 months).
    • Claustrophobia precluding chamber or hood tolerance.
    • Implanted devices not cleared for hyperbaric pressurization.
    • Pregnancy or plans to become pregnant during the study participation period. Women of childbearing potential will be asked to use an acceptable form of birth control during study participation.
    • Lung disease, such as emphysema, chronic bronchitis, asthma that is not well-controlled, or bullous lung disease that raises the risk for pulmonary barotrauma due to air trapping.
    • Active malignancy, previous malignancy (except basal cell carcinoma) in the last 5 years, or any prior treatment with bleomycin (Blenoxane). Prior treatment with doxorubicin (Adriamycin) is acceptable as long follow-up echocardiography is normal.
    • Chronic disease such as heart or renal failure would raise the participant's risk of adverse events during hyperbaric oxygen.
  • Confounds to the outcome assessments

    • Inability to speak English as their primary language (English fluency required because many of the outcomes are only in available in English)
    • Instability with walking requiring more than a cane for assistance
    • Alcohol abuse, by self-report, within the last year.
    • Lifetime history of illicit drug use, by self-report, except remote (greater than one year), non-habitual use of marijuana.
    • Failed urine drug screen during study participation.
    • Continued participation during the intervention period in sports activities where head injury is likely, such as contact football, boxing, mixed martial arts, etc.
    • Blind or deaf.
    • Major psychiatric disorder or degenerative mental disease (such as multiple sclerosis).
    • Prior therapeutic radiation to the central nervous system.
    • Personal history of any condition that pre-dates their brain injury that resulted in diminished capacity (such as chromosomal disorders) or that, in the opinion of the investigators, affects cognition to such a degree that the outcome assessments are invalidated (such as learning disability or attention deficit hyperactivity disorder requiring pharmaceutical therapy as an adult).
    • Any brain injury from stroke (ischemic or hemorrhagic)
    • Known untreated chronic or acute medical conditions, such as hypothyroidism, Cushing's disease, untreated hypertension, etc., that would confound the outcome assessments or inhibit compliance with the study protocol. If treated, these disorders would not be excluded.
    • Concomitant enrollment in any other drug/device clinical trial.
    • Prior hyperbaric oxygen for any reason within the last year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01986205

Layout table for location contacts
Contact: Michelle Fitts 801-408-3623
Contact: Susan Churchill, APRN-NP 801-408-3623

Layout table for location information
United States, Utah
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84157
Contact: Michelle Fitts    801-408-3623   
Principal Investigator: Lindell K. Weaver, MD         
Intermountain LDS Hospital Recruiting
Salt Lake City, Utah, United States, 84143
Contact: Michelle Fitts    801-408-3623   
Principal Investigator: Lindell K Weaver, MD         
Sponsors and Collaborators
Lindell Weaver
Layout table for investigator information
Principal Investigator: Lindell K. Weaver, MD Intermountain Health Care, Inc.
Layout table for additonal information
Responsible Party: Lindell Weaver, Medical Director, Hyperbaric Medicine, Intermountain Health Care, Inc. Identifier: NCT01986205    
Other Study ID Numbers: 1024845
First Posted: November 18, 2013    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Lindell Weaver, Intermountain Health Care, Inc.:
Traumatic brain injury
Hyperbaric oxygenation
Post-concussion symptoms
Carbon monoxide
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Injury, Chronic
Wounds and Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Brain Damage, Chronic